Notably, we also demonstrated that betulinic acid (BetA), a RELA agonist, showed promise in inhibiting tumor growth and metastasis in hepatomas with the TP53R249S mutation, potentially improving treatment outcomes and offering a novel strategic approach to liver cancer patients with TP53R249S mutation. Here, RELA is linked to neoplasm.